• linkedin
  • Increase Font
  • Sharebar

    Topical squalamine offers novel, promising therapy for nAMD

    Topical squalamine (Ohr Pharmaceutical), a small molecule being investigated for the treatment of neovascular age-related macular degeneration (nAMD) and other retinal vascular diseases, represents a novel therapy because of its mode of administration and multimodal mechanism of anti-angiogenic activity.

    Glenn L. Stoller, MD, chief scientific officer, Ohr Pharmaceutical, New York, outlined the mechanism of action of squalamine. He explained that it is a calmodulin-binding molecule that acts within vascular endothelial cells.

    The molecule enters the cells through cell membrane invaginations known as caveolae. Inside the cell, squalamine sequesters calmodulin away from its receptors and causes global suppression of calmodulin-dependent signaling that results in inhibition of VEGF- and basic fibroblast growth factor (bFGF)-mediated cell signaling, as well as decreased expression of cell surface integrins.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';